Multipotent mesenchymal stromal cells and the innate immune system

[1]  A. Fatica,et al.  Identity and ranking of colonic mesenchymal stromal cells , 2012, Journal of cellular physiology.

[2]  A. Cometa,et al.  Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation? , 2012, Bone Marrow Transplantation.

[3]  David H. Miller,et al.  Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study , 2012, The Lancet Neurology.

[4]  B. Nilsson,et al.  Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment , 2011, Current opinion in organ transplantation.

[5]  A. Le,et al.  Human Gingiva‐Derived Mesenchymal Stromal Cells Attenuate Contact Hypersensitivity via Prostaglandin E2‐Dependent Mechanisms , 2011, Stem cells.

[6]  G. Shaw,et al.  Mesenchymal stem cell inhibition of T‐helper 17 cell‐ differentiation is triggered by cell–cell contact and mediated by prostaglandin E2 via the EP4 receptor , 2011, European journal of immunology.

[7]  John D Lambris,et al.  Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL‐1β , 2011, Journal of cellular biochemistry.

[8]  D. Prockop,et al.  Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. , 2011, Blood.

[9]  Kazuya Sato,et al.  Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. , 2011, Cytotherapy.

[10]  R. Kaul,et al.  Identification of an innate T helper type 17 response to intestinal bacterial pathogens , 2011, Nature Medicine.

[11]  John D Lambris,et al.  Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses , 2011, PloS one.

[12]  R. Discipio,et al.  Mesenchymal stem cells and their microenvironment. , 2011, Frontiers in bioscience.

[13]  G. Pizzolo,et al.  Toll‐Like Receptor‐3‐Activated Human Mesenchymal Stromal Cells Significantly Prolong the Survival and Function of Neutrophils , 2011, Stem cells.

[14]  F. Mégraud,et al.  Human Bone Marrow-Derived Stem Cells Acquire Epithelial Characteristics through Fusion with Gastrointestinal Epithelial Cells , 2011, PloS one.

[15]  D. Mougiakakos,et al.  The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. , 2011, Blood.

[16]  T. Hohl,et al.  Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. , 2011, Immunity.

[17]  B. Mahon,et al.  Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells , 2011, Allergy.

[18]  D. Metcalfe,et al.  Bone marrow stromal cells inhibit mast cell function via a COX2‐dependent mechanism , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  F. Carrión,et al.  Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. , 2011, Immunology letters.

[20]  F. Di Virgilio,et al.  Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. , 2011, Experimental hematology.

[21]  Kazuo Suzuki,et al.  Interferon-γ Regulates the Proliferation and Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3 Dioxygenase (IDO) , 2011, PloS one.

[22]  M. Merad,et al.  Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche , 2011, The Journal of experimental medicine.

[23]  R. Childs,et al.  Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. , 2011, Cytotherapy.

[24]  Xin Chen,et al.  Mesenchymal cells of the intestinal lamina propria. , 2011, Annual review of physiology.

[25]  G. Supic,et al.  Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists. , 2011, Stem cells and development.

[26]  Franco Locatelli,et al.  Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease , 2011, Gut.

[27]  D. Mougiakakos,et al.  Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. , 2011, Blood.

[28]  R. Henschler,et al.  Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase , 2011, Leukemia.

[29]  Gabriel Courties,et al.  IL-6-Dependent PGE2 Secretion by Mesenchymal Stem Cells Inhibits Local Inflammation in Experimental Arthritis , 2010, PloS one.

[30]  J. Lévesque,et al.  Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. , 2010, Blood.

[31]  M. Matthay,et al.  Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL‐37 , 2010, Stem cells.

[32]  F. Bootz,et al.  Tissue‐resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge , 2010, Journal of leukocyte biology.

[33]  K. Kang,et al.  Implication of NOD1 and NOD2 for the Differentiation of Multipotent Mesenchymal Stem Cells Derived from Human Umbilical Cord Blood , 2010, PloS one.

[34]  Arthur S Slutsky,et al.  Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. , 2010, American journal of respiratory and critical care medicine.

[35]  D. Hommes,et al.  Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study , 2010, Gut.

[36]  H. Atkins,et al.  Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis , 2010, Annals of neurology.

[37]  T. Salo,et al.  Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13. , 2010, Experimental cell research.

[38]  N. Fujii,et al.  The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. , 2010, Immunity.

[39]  Ben D. MacArthur,et al.  Mesenchymal and haematopoietic stem cells form a unique bone marrow niche , 2010, Nature.

[40]  C. Jorgensen,et al.  Mesenchymal Stem Cells Inhibit Human Th17 Cell Differentiation and Function and Induce a T Regulatory Cell Phenotype , 2010, The Journal of Immunology.

[41]  E. Lombardo,et al.  Modulation of Adult Mesenchymal Stem Cells Activity by Toll-Like Receptors: Implications on Therapeutic Potential , 2010, Mediators of inflammation.

[42]  P. Laloi,et al.  Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis , 2010, Cell Death and Differentiation.

[43]  Steven J. Greco,et al.  Mesenchymal Stem Cells Protect Breast Cancer Cells through Regulatory T Cells: Role of Mesenchymal Stem Cell-Derived TGF-β , 2010, The Journal of Immunology.

[44]  F. Bootz,et al.  Human nasal mucosa contains tissue-resident immunologically responsive mesenchymal stromal cells. , 2010, Stem cells and development.

[45]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[46]  Y. Lau,et al.  Phagocytosis of Apoptotic Cells Modulates Mesenchymal Stem Cells Osteogenic Differentiation to Enhance IL‐17 and RANKL Expression on CD4+ T Cells , 2010, Stem cells.

[47]  Ruth S. Waterman,et al.  A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype , 2010, PloS one.

[48]  Y. Sawa,et al.  Reduction of N-glycolylneuraminic acid xenoantigen on human adipose tissue-derived stromal cells/mesenchymal stem cells leads to safer and more useful cell sources for various stem cell therapies. , 2010, Tissue engineering. Part A.

[49]  A. Boudabous,et al.  Evidence for the Involvement of Galectin‐3 in Mesenchymal Stem Cell Suppression of Allogeneic T‐Cell Proliferation , 2010, Scandinavian journal of immunology.

[50]  A. Keane-Myers,et al.  Bone marrow stromal cells use TGF-β to suppress allergic responses in a mouse model of ragweed-induced asthma , 2010, Proceedings of the National Academy of Sciences.

[51]  P. Martiat,et al.  Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. , 2010, Human immunology.

[52]  H. Bu,et al.  Mesenchymal stem cells inhibit complement activation by secreting factor H. , 2010, Stem cells and development.

[53]  S. Raiden,et al.  Mouse Bone Marrow-Derived Mesenchymal Stromal Cells Turn Activated Macrophages into a Regulatory-Like Profile , 2010, PloS one.

[54]  M. Tate,et al.  Neutrophils Ameliorate Lung Injury and the Development of Severe Disease during Influenza Infection1 , 2009, The Journal of Immunology.

[55]  Catherine Ghezzi,et al.  Intravenous Administration of 99mTc-HMPAO-Labeled Human Mesenchymal Stem Cells after Stroke: In Vivo Imaging and Biodistribution , 2009, Cell transplantation.

[56]  P. Hematti,et al.  Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. , 2009, Experimental hematology.

[57]  D. Covas,et al.  Mechanisms involved in the therapeutic properties of mesenchymal stem cells. , 2009, Cytokine & growth factor reviews.

[58]  M. Netea,et al.  Toll-like receptor triggering in cord blood mesenchymal stem cells , 2009, Journal of cellular and molecular medicine.

[59]  S. Miller,et al.  Human bone marrow‐derived mesenchymal stem cells induce Th2‐polarized immune response and promote endogenous repair in animal models of multiple sclerosis , 2009, Glia.

[60]  P. Delafontaine,et al.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. , 2009, Cell stem cell.

[61]  R. Gutiérrez,et al.  Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. , 2009, Histology and histopathology.

[62]  E. Lombardo,et al.  Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. , 2009, Tissue Engineering. Part A.

[63]  R. Romieu-Mourez,et al.  Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype1 , 2009, The Journal of Immunology.

[64]  Zhaojun Wang,et al.  Lipopolysaccharides can protect mesenchymal stem cells (MSCs) from oxidative stress‐induced apoptosis and enhance proliferation of MSCs via Toll‐like receptor(TLR)‐4 and PI3K/Akt , 2009, Cell biology international.

[65]  Philippe M. Campeau,et al.  Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Inhibiting CD4 Th17 T Cells in a CC Chemokine Ligand 2-Dependent Manner1 , 2009, The Journal of Immunology.

[66]  G. Daley,et al.  Bone marrow adipocytes as negative regulators of the hematopoietic microenvironment , 2009, Nature.

[67]  M. Weller,et al.  Toll‐Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow‐Derived Mesenchymal Stem Cells by Inducing Indoleamine‐2,3‐dioxygenase‐1 via Interferon‐β and Protein Kinase R , 2009, Stem cells.

[68]  Jae W. Lee,et al.  Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung , 2009, Proceedings of the National Academy of Sciences.

[69]  L. Zon,et al.  Genetic Interaction of PGE2 and Wnt Signaling Regulates Developmental Specification of Stem Cells and Regeneration , 2009, Cell.

[70]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[71]  Ming Zhao,et al.  C3a and C5a Are Chemotactic Factors for Human Mesenchymal Stem Cells, Which Cause Prolonged ERK1/2 Phosphorylation1 , 2009, The Journal of Immunology.

[72]  Jeffrey M Karp,et al.  Mesenchymal stem cell homing: the devil is in the details. , 2009, Cell stem cell.

[73]  F. Benvenuto,et al.  Reciprocal Interactions Between Human Mesenchymal Stem Cells and γδ T Cells Or Invariant Natural Killer T Cells , 2009, Stem cells.

[74]  C. Toma,et al.  Fate Of Culture-Expanded Mesenchymal Stem Cells in The Microvasculature: In Vivo Observations of Cell Kinetics , 2009, Circulation research.

[75]  D. Büscher,et al.  Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis , 2009, Gut.

[76]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[77]  Haitao Wen,et al.  TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events , 2008, The Journal of experimental medicine.

[78]  S. Akira,et al.  TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. , 2008, Blood.

[79]  A. Barrett,et al.  Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[80]  Y. Lau,et al.  Prolonged exposure to bacterial toxins downregulated expression of toll-like receptors in mesenchymal stromal cell-derived osteoprogenitors , 2008, BMC Cell Biology.

[81]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[82]  P. Veys,et al.  Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. , 2008, Blood.

[83]  Hyunjin Cho,et al.  Role of MyD88 in TLR agonist-induced functional alterations of human adipose tissue-derived mesenchymal stem cells , 2008, Molecular and Cellular Biochemistry.

[84]  S. Setty,et al.  IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease , 2008, European journal of immunology.

[85]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[86]  V. Barnaba,et al.  Immunogenicity of Human Mesenchymal Stem Cells in HLA‐Class I‐Restricted T‐Cell Responses Against Viral or Tumor‐Associated Antigens , 2008, Stem cells.

[87]  Liwen Chen,et al.  Paracrine Factors of Mesenchymal Stem Cells Recruit Macrophages and Endothelial Lineage Cells and Enhance Wound Healing , 2008, PloS one.

[88]  Daniel Lucas,et al.  Haematopoietic stem cell release is regulated by circadian oscillations , 2008, Nature.

[89]  R. Zhao,et al.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell stem cell.

[90]  L. Moretta,et al.  Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. , 2008, Blood.

[91]  F. Montecucco,et al.  Human Mesenchymal Stem Cells Inhibit Neutrophil Apoptosis: A Model for Neutrophil Preservation in the Bone Marrow Niche , 2008, Stem cells.

[92]  L. Cosmi,et al.  Toll‐Like Receptors 3 and 4 Are Expressed by Human Bone Marrow‐Derived Mesenchymal Stem Cells and Can Inhibit Their T‐Cell Modulatory Activity by Impairing Notch Signaling , 2008, Stem cells.

[93]  Ruth S. Waterman,et al.  Toll‐Like Receptors on Human Mesenchymal Stem Cells Drive Their Migration and Immunomodulating Responses , 2008, Stem cells.

[94]  N. Rouas-Freiss,et al.  Human Leukocyte Antigen‐G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells , 2008, Stem cells.

[95]  M. Veldhoen,et al.  Th17 T cells: linking innate and adaptive immunity. , 2007, Seminars in immunology.

[96]  D. Prockop,et al.  Concise Review: Mesenchymal Stem/Multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair—Current Views , 2007, Stem cells.

[97]  B. Sacchetti,et al.  Self-Renewing Osteoprogenitors in Bone Marrow Sinusoids Can Organize a Hematopoietic Microenvironment , 2007, Cell.

[98]  D. Prockop,et al.  “Stemness” Does Not Explain the Repair of Many Tissues by Mesenchymal Stem/Multipotent Stromal Cells (MSCs) , 2007, Clinical pharmacology and therapeutics.

[99]  John D Lambris,et al.  The role of complement in inflammatory diseases from behind the scenes into the spotlight. , 2007, The American journal of pathology.

[100]  Jae W. Lee,et al.  Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice1 , 2007, The Journal of Immunology.

[101]  L. Ortiz,et al.  Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury , 2007, Proceedings of the National Academy of Sciences.

[102]  F. Barry,et al.  IFN-γ and TNF-α differentially regulate immunomodulation by murine mesenchymal stem cells , 2007 .

[103]  S. Smirnov,et al.  Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection: implications for hematopoiesis, self-renewal and differentiation potential. , 2007, Virology.

[104]  M. Pevsner-Fischer,et al.  Toll-like receptors and their ligands control mesenchymal stem cell functions. , 2007, Blood.

[105]  S. Bischoff.  Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data , 2007, Nature Reviews Immunology.

[106]  Sarah L. Brown,et al.  Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. , 2007, The Journal of clinical investigation.

[107]  T. Nagasawa,et al.  Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. , 2006, Immunity.

[108]  Y. Bae,et al.  Role of Toll‐Like Receptors on Human Adipose‐Derived Stromal Cells , 2006, Stem cells.

[109]  Anoop P. Patel,et al.  Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. , 2006, Blood.

[110]  P. Schwarzenberger,et al.  Interleukin‐17A: A T‐Cell‐Derived Growth Factor for Murine and Human Mesenchymal Stem Cells , 2006, Stem cells.

[111]  L. Moretta,et al.  Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. , 2006, Blood.

[112]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[113]  A. Trumpp,et al.  Bone-marrow haematopoietic-stem-cell niches , 2006, Nature Reviews Immunology.

[114]  S. Perez,et al.  Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells , 2006, Stem cells.

[115]  M. Gobbi,et al.  Interaction between Human NK Cells and Bone Marrow Stromal Cells Induces NK Cell Triggering: Role of NKp30 and NKG2D Receptors1 , 2005, The Journal of Immunology.

[116]  O. Koç,et al.  Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. , 2005, Experimental hematology.

[117]  P. Rameshwar,et al.  A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge. , 2005, Experimental hematology.

[118]  E. Thiel,et al.  Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. , 2005, Experimental hematology.

[119]  M. Abreu,et al.  TLR Signaling in the Gut in Health and Disease1 , 2005, The Journal of Immunology.

[120]  C. Robin,et al.  Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny , 2005, Development.

[121]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[122]  N. Wright,et al.  STEM CELL IN GASTROINTESTINAL STRUCTURE AND NEOPLASTIC DEVELOPMENT , 2004, Gut.

[123]  M. Ratajczak,et al.  Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. , 2004, Blood.

[124]  O. Ringdén,et al.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells , 2003, Transplantation.

[125]  D. Scadden,et al.  Osteoblastic cells regulate the haematopoietic stem cell niche , 2003, Nature.

[126]  T. Ganz.  Epithelia: Not just physical barriers , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[127]  G. Kopen,et al.  MicroSAGE Analysis of 2,353 Expressed Genes in a Single Cell‐Derived Colony of Undifferentiated Human Mesenchymal Stem Cells Reveals mRNAs of Multiple Cell Lineages , 2001, Stem cells.

[128]  M. Bachmann,et al.  On the Role of the Innate Immunity in Autoimmune Disease , 2001, The Journal of experimental medicine.

[129]  S. Colla,et al.  Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation , 2000 .

[130]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[131]  Friedenstein Aj,et al.  Marrow microenvironment transfer by heterotopic transplantation of freshly isolated and cultured cells in porous sponges. , 1982 .

[132]  E. Luria,et al.  Fibroblast Colony Formation from Monolayer Cultures of Blood Cells , 1971, Transfusion.

[133]  Jacques Galipeau,et al.  Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[134]  F. Lanza,et al.  Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. , 2009, Cytotherapy.

[135]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[136]  Yasuyuki Fujita,et al.  Mesenchymal Stem Cells Are Recruited into Wounded Skin and Contribute to Wound Repair by Transdifferentiation into Multiple Skin Cell Type , 2008 .

[137]  L. Moretta,et al.  Mesenchymal stem cells inhibit natural killer – cell proliferation , cytotoxicity , and cytokine production : role of indoleamine 2 , 3-dioxygenase and prostaglandin E 2 , 2008 .

[138]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[139]  I. Marriott.  Osteoblast responses to bacterial pathogens , 2004, Immunologic research.

[140]  S. Colla,et al.  Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. , 2000, Blood.

[141]  S. Gerson,et al.  Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  R. Schofield.  The stem cell system. , 1983, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[143]  A. Friedenstein,et al.  Marrow microenvironment transfer by heterotopic transplantation of freshly isolated and cultured cells in porous sponges. , 1982, Experimental hematology.